Strides Arcolab invests in Oncobiologics Inc, acquires stake

Image
Press Trust of India New Delhi
Last Updated : Jul 17 2014 | 12:57 PM IST
Drug firm Strides Arcolab has made a series of investments in bio-pharmaceutical firm Oncobiologics Inc, acquiring a stake in the US based company.
Strides Arcolab and Oncobiologics Inc said in a statement today that Strides has made a series of strategic investments in privately held New Jersey biopharma firm Oncobiologics Inc.
The two companies, however, did not provide the financial details of the investments.
According to a source, Strides Arcolab has acquired a stake in the US firm.
Commenting on the development, Strides Arcolab Founder and Group CEO Arun Kumar said: "After significant due diligence, it is evident that their (Oncobiologics Inc) success to-date in meeting technical milestones is an indicator of the solid team and business model they have constructed."
The investment is part of Strides' strategy to fund biopharma companies with high quality scientific management and proprietary approaches to developments that confer significant time and cost advantages, the statement said.
"The investments by Strides Arcolab represent important milestones for Oncobiologics. Strides Arcolab is a long-term strategic partner that provides both financial strength and a proven track-record of successful business ventures," Oncobiologics Founder & CEO, Pankaj Mohan said.
Shares of Strides Arcolab were today trading at Rs 667.60 per scrip in the morning trade on BSE, up 2.54 per cent from its previous close.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jul 17 2014 | 12:57 PM IST

Next Story